Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Executive Summary

Historical Document

This Web site is provided by the Agency for Toxic Substances and Disease Registry (ATSDR)
ONLY as an historical reference for the public health community. It is no longer being maintained and the data
it contains may no longer be current and/or accurate.

Seven expert panelists reviewed and discussed the state of the science on how
fiber length relates to toxicity of asbestos and synthetic vitreous fibers (SVFs)—an
issue relevant to the Agency for Toxic Substances and Disease Registry's (ATSDR's)
ongoing work at several sites where fiber contamination is found in or near
residential neighborhoods. The expert panelists included epidemiologists, pathologists,
physicians, hygienists, pulmonologists, and toxicologists. During a 2-day meeting
in October 2002 in New York City, the panelists thoroughly discussed the physiological
fate of structures less than 5 micrometers (µm) in length having aspect
ratios greater than 3:1, health effects of asbestos and SVFs of the same dimensions,
and research needs.

The panelists' main findings and recommendations are listed below. The remainder
of this report summarizes the discussions and observations that led to these
findings, and reviews the panelists' comments on many topics not listed in this
executive summary. This report provides insights and advice on how to interpret
exposures to asbestos and SVFs less than 5 µm in length based on panelist
discussions; however, the contents of this report should not be considered ATSDR
policy.

Factors that influence toxicity. Health effects from asbestos
and SVFs ultimately are functions of fiber dose, fiber dimension (length and
diameter), and fiber durability or persistence in the lung (as determined
by the mineral type, the amorphous or crystalline structure, and the surface
chemistry).

Fibers or particles? Some panelists questioned why structures
less than 5 µm long, regardless of their aspect ratio, were referred
to as "fibers." This report refers to structures less than 5 µm
long as "fibers," while acknowledging that some expert panelists
have reservations about this terminology.

Deposition and retention of short fibers. The lung depositional
patterns of fibers less than 5 µm long have been well established and
depend almost entirely on fiber width. For short fibers with diameters between
0.1 and 1.6 µm, total lung deposition in healthy people will be between
10% and 20% of what is inhaled, with most of that deposition occurring in
the deep lung; the fibers that do not deposit will be exhaled. For short fibers
with diameters less than 0.1 µm, a greater proportion will deposit and
there will be a somewhat greater proportion of deposition in the proximal
airways.

The short fibers can be cleared from the lung by various mechanisms, depending
on where the fibers deposit. Fibers depositing on the surface of conductive
airways (i.e., the tracheobronchial region) are efficiently cleared by the
mucociliary escalator, generally within 24 hours. Many of the short fibers
that reach the gas exchange region of the lung are cleared by alveolar macrophages,
and the rate of clearance by phagocytosis has been found to vary with fiber
length and to differ across mammalian species. One panelist, for instance,
cited studies of mice and rats suggesting that phagocytosis clears
short fibers from the alveolar regions of the lung within a few weeks following
exposure. On the other hand, another panelist noted that researchers have
established that alveolar macrophage mediated clearance in human
lungs takes considerably longer (retention half-times of 400 to 700 days).
Overall, panelists noted that rodents clear short fibers from their lungs
approximately 10 times faster than do humans. Deposition and retention patterns
may differ in people with impaired capacities to clear foreign material from
their lungs. The extent to which short fibers preferentially translocate from
the gas exchange region to the pleura is not well known.

Cancer effects of short fibers. Given findings from epidemiologic
studies, laboratory animal studies, and in vitro genotoxicity studies,
combined with the lung's ability to clear short fibers, the panelists agreed
that there is a strong weight of evidence that asbestos and SVFs shorter than
5 µm are unlikely to cause cancer in humans.

Noncancer effects of short fibers. The laboratory animal
studies, epidemiologic studies, and in vitro studies generally suggest
that asbestos and SVF pathogenicity increases with fiber length, but there
are several notable exceptions. In laboratory animals, for example, short
asbestos and SVFs at sufficiently high doses have been shown to cause inflammation,
pulmonary interstitial fibrosis, and pleural reactions; however, the doses
needed to cause these effects in humans may not be relevant to environmental
exposures. In humans, four epidemiologic studies (Churg et al. 1989, 1990;
Nayebzadeh et al. 2001; Case 2002b) involving highly exposed workers found
that pulmonary interstitial fibrosis is correlated with the amount of short
fibers in the lung at death; some researchers have hypothesized that
this apparent association is explained by long fibers breaking down into shorter
fibers between exposure and the time at which lung samples were collected.
Finally, at least two in vitro studies (Ye et al. 1999, 2001) have
found that short fibers are at least as active as, if not more active than,
long fibers on a surface area or mass basis for multiple endpoints (e.g.,
tumor necrosis factor-alpha [TNF-a] production,
activation of TNF-a gene promoter activity); however,
the relevance of these in vitro findings to health effects in vivo
is not known. Taken together, the findings from the laboratory animal, epidemiologic,
and in vitro studies suggest that short fibers may be pathogenic
for pulmonary fibrosis, and further research is needed to clarify this issue.

Research needs and recommendations. Throughout the meeting,
the panelists identified data gaps and made recommendations for filling them.
Some recommendations addressed issues specific to sites (e.g., Libby, Montana;
Lower Manhattan) with concerns about short fibers in residential communities.
These recommendations are listed in Section 4.1.
The panelists' recommendations for general research projects follow, in no
particular order:

Encourage increased use of sampling human lung tissue or other biological
indices, such as sputum collection, in known or suspected human exposure
situations to improve both qualitative and quantitative exposure assessment.

Conduct a laboratory animal study to characterize the extent to which
fibers of all lengths translocate into the pleura, and whether the translocation
preferentially occurs for fibers of any dimension or type. Some panelists
noted that translocation of fibers into the pleura does not necessarily
imply causation of pleural disease, the mechanisms and site of action
of these mechanisms being unknown (Kane et al. 1996). One panelist indicated
that some studies (e.g., Gelzeichter et al. 1996; McConnell et al. 1999)
have already examined this issue, to a certain extent, for refractory
ceramic fibers; and a follow-up study has recently been completed, but
not yet published, for amphibole fibers.

Develop and adopt standardized environmental and biologic sampling
and analytical protocols to ensure that samples collected from different
sites for different purposes can be compared.

Perform personal exposure sampling, or an equivalent, to quantify what
exposures result when household surfaces are contaminated with asbestos
or SVFs; analyze samples using conventional fiber counting methods (i.e.,
counting only fibers longer than 5 µm), but archive a subset of
filter samples for further analysis.

Further investigate the possible association between short fibers and
pulmonary interstitial fibrosis in humans and the impact of short fibers
in regard to pleural changes, such as pleural plaques and diffuse pleural
fibrosis.

Design and conduct an in vitro study to characterize the influence
of fiber length on cell proliferation, DNA damage, and cytotoxicity endpoints
that can then be confirmed in animal studies.